Linked Life Data

16956452

Source:http://linkedlifedata.com/resource/pubmed/id/16956452

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-9-7
pubmed:abstractText
With remarkable advancement in technology and clinical research, implantable cardioverter defibrillators (ICDs) have replaced antiarrhythmic drugs as the preferred modality for both primary and secondary prevention of arrhythmic deaths. However, concomitant use of antiarrhythmics in patients with ICDs remains common, often for prevention or reduction of appropriate and inappropriate shocks caused by ventricular and supraventricular arrhythmias, respectively. The role of empiric antiarrhythmic therapy in this patient population remains less clearly defined, with conflicting information from various small randomized trials. Use of antiarrhythmic drugs in the ICD patient population not only can cause potentially serious side effects but can also interact or interfere with the ICD device function. In addition, the effect on survival in patients with ICDs is not well characterized. Given the many potential side effects, drug-device interactions, unclear survival effect, and lack of convincing clinical data supporting its use, empiric antiarrhythmic therapy in the ICD patient population cannot be recommended at this time.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1523-3782
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
365-9
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Is there a role for antiarrhythmic drugs in patients with implantable defibrillators?
pubmed:affiliation
Section of Cardiology, University of Southern California/Keck School of Medicine, 1510 San Pablo Street, #322,Los Angeles, CA 90033, USA.
pubmed:publicationType
Journal Article, Review